Financials in USD. Standardized financial statements.
A compact view of how Harmony Biosciences Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M | $6.00M | $0 |
| Revenue Growth? | +21.5% | +22.8% | +32.9% | +43.4% | +91.2% | +2564.6% | 0.0% | 0.0% |
| Cost of Revenue? | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M | $1.58M | $184,000 |
| Gross Profit? | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M | $4.42M | -$184,000 |
| Gross Margin? | +77.2% | +78.1% | +79.2% | +80.9% | +81.8% | +82.6% | +73.7% | 0.0% |
| Operating Expenses? | $461.64M | $367.09M | $268.76M | $234.19M | $162.39M | $115.02M | $150.32M | $41.44M |
| Operating Income? | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M | -$145.90M | -$41.44M |
| EBITDA? | $255.05M | $233.41M | $221.51M | $146.87M | $80.46M | $1.51M | -$142.69M | -$41.26M |
| Income Before Tax | $215.06M | $191.80M | $173.40M | $104.69M | $37.43M | -$36.94M | -$151.98M | -$39.90M |
| Income Tax Expense | $56.38M | $46.31M | $44.54M | -$76.78M | $2.83M | $0 | $0 | $0 |
| Net Income? | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M | -$36.94M | -$151.98M | -$39.90M |
| EPS? | $2.76 | $2.56 | $2.17 | $3.07 | $0.60 | $-1.12 | $-2.94 | $-1.42 |
| Diluted EPS? | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-1.10 | $-2.94 | $-1.42 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality